NOVARTIS INDIA Latest Share Price (NOVARTIND)
TODAY IN ONE LINE
NOVARTIND rose 1.3% on average volume, outperforming Nifty's -1.1% move.
With a market cap of ₹4,752.98 Cr., it trades at a P/E of 48.61. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
NOVARTIS INDIA flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Quarterly OutperformanceLatest quarter Sales up 14.6% and Profit up 27.6%
- ●Healthy Operating MarginsOPM is structurally strong at 37.0%
- ●High Promoter HoldingPromoters hold 70.7% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 13.8% YoY
Latest NOVARTIS INDIA News
What changed recently?
Recent events, corporate actions, and announcements.
NOVARTIS INDIA valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for NOVARTIS INDIA, framed against the sector median so the premium or discount is obvious at a glance.
NOVARTIS INDIA trades at a P/E of 48.61× and P/B of 5.81×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
NOVARTIS INDIA technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for NOVARTIS INDIA — derived from the latest tape, not yesterday's close.
NOVARTIS INDIA last traded at ₹1,921.6 with an intraday range of ₹1,869.7–₹1,940 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹1921.60| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 2091.77 | +170.17 | +8.86% |
| R3 | 2021.47 | +99.87 | +5.20% |
| R2 | 1980.73 | +59.13 | +3.08% |
| R1 | 1951.17 | +29.57 | +1.54% |
| PIVOT | 1910.43 | -11.17 | -0.58% |
| CURRENT | 1921.60 | — | — |
| S1 | 1880.87 | -40.73 | -2.12% |
| S2 | 1840.13 | -81.47 | -4.24% |
| S3 | 1810.57 | -111.03 | -5.78% |
| S4 | 1740.27 | -181.33 | -9.44% |
NOVARTIND is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹1869.7–₹1888.1
Trading Inside opening range
NOVARTIS INDIA financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for NOVARTIS INDIA — consolidated or standalone — with margins, YoY growth and key ratios inline.
NOVARTIS INDIA reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹4,752.98 Cr. and reported EPS of ₹13.05.
NOVARTIS INDIA segment analysis : revenue and profit mix.
Disclosed business segments at NOVARTIS INDIA with their share of revenue and profit, switchable between consolidated and standalone reporting.
NOVARTIS INDIA discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for NOVARTIS INDIA.
Our AI distills the core fundamental drivers supporting NOVARTIS INDIA, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
What you're getting.
No strengths or opportunities on record.
Key Risks.
No weaknesses or threats on record.
Flip Conditions.
Valuation risk. a P/E above 63 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
NOVARTIS INDIA peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — NOVARTIS INDIA is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
NOVARTIS INDIA chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for NOVARTIS INDIA — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
NOVARTIS INDIA delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for NOVARTIS INDIA over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in NOVARTIS INDIA stood at 49.6% of traded volume, against a 20-day average of 41.2%.
NOVARTIS INDIA announcements: results, concalls, ratings, M&A.
Filings NOVARTIS INDIA sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
NOVARTIS INDIA files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 70 documents below.
AGM/EGM
Intimation of the Voting Results and the Scrutinizers Report for the 78th Annual General Meeting of the Company held on Thursday, September 24, 2026.
AGM/EGM
Intimation of the proceedings of the 78th Annual General Meeting of Novartis India Limited held on September 24, 2026.
Company Update
Intimation is hereby given that the Officials of the Company will be participating in the Conference / Meeting scheduled on Emerging India CEO Forum…
Company Update
Intimation regarding the newspaper publication made regarding the Corrigendum filed dated September 18, 2026, for the Notice of 78th Annual General…
AGM/EGM
Corrigendum to the Notice of 78th Annual General Meeting dated August 27, 2026
Investor decks & rating reports.
NOVARTIS INDIA dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue NOVARTIS INDIA has declared, sequenced by announce and record date.
NOVARTIS INDIA corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About NOVARTIS INDIA: business, sector, key facts.
What NOVARTIS INDIA does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
NOVARTIS INDIA operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: NOVARTIND, BSE: 500672.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- 3B BLACKBIO DX (3BBLACKBIO) Share PricePeer
- ABBOTT INDIA (ABBOTINDIA) Share PricePeer
- ACUTAAS CHEMICALS (ACUTAAS) Share PricePeer
- ANLON HEALTHCARE (AHCL) Share PricePeer
- AMANTA (AMANTA) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about NOVARTIS INDIA (NOVARTIND).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of NOVARTIS INDIA (NOVARTIND)?
The current share price of NOVARTIS INDIA (NOVARTIND) is ₹1,921.60. Today, the stock has gained by ₹24.00 (1.26%), trading in a range of ₹1,869.70 to ₹1,940.00. The stock opened at ₹1,888.10 with a trading volume of 12,000 shares.
02Is NOVARTIS INDIA stock a good investment for long-term?
NOVARTIS INDIA can be considered for long-term investment based on several factors. The company has a market capitalization of ₹4,752.98 Cr., P/E ratio of 48.61, ROE of 11.39%, and ROCE of 14.33%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of NOVARTIS INDIA stock?
The 52-week high price of NOVARTIS INDIA (NOVARTIND) is ₹2,588.80, while the 52-week low is ₹950.00. Currently trading at ₹1,921.60, the stock is 102.27% above its 52-week low and 25.77% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy NOVARTIS INDIA stock at the current price?
Whether to buy NOVARTIS INDIA stock at ₹1,921.60 depends on multiple factors. The stock is currently trading with a P/E ratio of 48.61 and P/B ratio of 5.81. Today's performance shows a gain of 1.26%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of NOVARTIS INDIA and when is the next dividend?
NOVARTIS INDIA offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹1,921.60, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹5.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of NOVARTIS INDIA?
NOVARTIS INDIA's key financial metrics include: P/E Ratio: 48.61, P/B Ratio: 5.81, ROE: 11.39%, ROCE: 14.33%, Dividend Yield: 0%, EPS: ₹13.05, Book Value: ₹331.23, and Debt-to-Equity: 0. The company's market cap stands at ₹4,752.98 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is NOVARTIS INDIA stock performing today in the market?
NOVARTIS INDIA stock opened at ₹1,888.10 and is currently trading at ₹1,921.60, showing a gain of ₹24.00 (1.26%). The intraday high is ₹1,940.00 and low is ₹1,869.70. The trading volume stands at 12,000 shares, indicating moderate market participation today.
08What is the P/E ratio of NOVARTIS INDIA and what does it indicate?
NOVARTIS INDIA has a Price-to-Earnings (P/E) ratio of 48.61, which means investors are willing to pay 48.61 for every ₹1 of earnings. With an EPS of ₹13.05, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about NOVARTIS INDIA (NOVARTIND) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.